The Latest Breaking News on Pharma

McKesson earnings beat estimates, but the drug and health supplies distribution giant badly missed sales estimates.

Acadia Pharmaceuticals led a biotech stock sell-off Wednesday after revenue from its Rett syndrome treatment missed expectations.

Pet medications wholesaler PetIQ agreed to a $1.5 billion buyout Wednesday, sending shares into the stratosphere.

Halozyme Therapeutics obliterated second-quarter expectations, and the No. 1 biotech stock jumped early Wednesday.

TG Therapeutics stock popped Tuesday after the drugmaker unexpectedly reported a second-quarter profit, thanks to significantly lower R&D.

With highly effective drugs and treatment options, chronic disease prevalence, and adoption of technology, the biotech market is thriving. Hence, fundamentally solid biotech stocks Illumina (ILMN), Amgen (AMGN), and Entrada Therapeutics (TRDA) could be ideal with anticipated strong earnings reports. Read more.

Moderna stock, which lost 27% of its value over two days, tumbled again Monday on a rare downgrade amid uncertainty for its vaccines.

America’s drugstores are testing smaller locations and more ways to offer care as more store closings loom

Moderna cut its outlook early Thursday despite delivering nearly double strong quarterly sales. Moderna stock tumbled.

Emma Walmsley’s overhaul seems to be delivering the goods even if US worries have left the share price becalmed

Pfizer reported a notable year-over-year decline in Q2 earnings, but the results still beat expectations. Here's what investors should know.